Free Trial

Small Cap Stocks Worth Watching - September 30th

Spring Valley Acquisition logo with Consumer Staples background

Key Points

  • Five Small Cap stocks to watch include Spring Valley Acquisition, Beneficient, Draganfly, Virios Therapeutics, and Innovation Beverage Group, identified for their high trading volume recently.
  • Beneficient offers liquidity solutions and related services in the alternative asset industry, leveraging its segments for financial growth.
  • Virios Therapeutics is focused on developing novel antiviral therapies, with its lead candidate aimed at treating fibromyalgia through a unique combination treatment.
  • MarketBeat previews top five stocks to own in October.

Spring Valley Acquisition, Beneficient, Draganfly, Virios Therapeutics, and Innovation Beverage Group are the five Small Cap stocks to watch today, according to MarketBeat's stock screener tool. Small-cap stocks are shares of publicly traded companies whose total market value typically falls between about $300 million and $2 billion. Because these businesses are smaller and often in earlier growth stages, they can offer investors the potential for above-average returns as they expand—but they also tend to be more volatile and carry higher risk than larger, more established firms. These companies had the highest dollar trading volume of any Small Cap stocks within the last several days.

Spring Valley Acquisition (SV)

Read Our Latest Research Report on SV

Beneficient (BENF)

Beneficient, a technology-enabled financial services company, provides liquidity solutions and related trustee, custody and trust administrative services to participants in the alternative asset industry in the United States. It operates through Ben Liquidity, Ben Custody, and Customer ExAlt Trusts segments.

Read Our Latest Research Report on BENF

Draganfly (DPRO)

Draganfly Inc. develops, manufactures, and sells cutting-edge unmanned and remote data collection and analysis platforms and systems in the United States and Canada. The company offers quadcopters, fixed-wing aircraft, ground-based robots, handheld controllers, and flight training, as well as software used for tracking, live streaming, and data collection.

Read Our Latest Research Report on DPRO

Virios Therapeutics (VIRI)

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.

Read Our Latest Research Report on VIRI

Innovation Beverage Group (IBG)

Read Our Latest Research Report on IBG

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Spring Valley Acquisition Right Now?

Before you consider Spring Valley Acquisition, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spring Valley Acquisition wasn't on the list.

While Spring Valley Acquisition currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.